相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study
Claudia Weiss et al.
LANCET CHILD & ADOLESCENT HEALTH (2022)
SMN protein is required throughout life to prevent spinal muscular atrophy disease progression
Xin Zhao et al.
HUMAN MOLECULAR GENETICS (2022)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
Eugenio Mercuri et al.
LANCET NEUROLOGY (2021)
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue
Gretchen Thomsen et al.
NATURE MEDICINE (2021)
Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes
Natalia N. Singh et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)
A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases
Jonathan M. Fischell et al.
FRONTIERS IN NEUROSCIENCE (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
John W. Day et al.
LANCET NEUROLOGY (2021)
Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit
Meaghan Van Alstyne et al.
NATURE NEUROSCIENCE (2021)
Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next
Brunhilde Wirth et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 21, 2020 (2020)
RNA in spinal muscular atrophy: therapeutic implications of targeting
Ravindra N. Singh et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy
Anna A. L. Motyl et al.
HUMAN MOLECULAR GENETICS (2020)
The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy
Ravindra N. Singh et al.
NEUROSCIENCE INSIGHTS (2020)
MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates
Juliette Hordeaux et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
AVXS-101 (Onasemnogene Abeparvovec) for SMA 1: Comparative Study with a Prospective Natural History Cohort
Samiah A. Al-Zaidy et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2019)
Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
Christian Hinderer et al.
HUMAN GENE THERAPY (2018)
How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy
N. N. Singh et al.
GENE THERAPY (2017)
Diverse role of survival motor neuron protein
Ravindra N. Singh et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2017)